(Reuters) – GSK Plc said on Friday it “respectfully disagrees” with a ruling by a California state court in litigation related to claims that the company’s heartburn drug, Zantac, caused cancer.
The London-listed shares of the company were down about 4% as of 1020 GMT.
(Reporting by Aby Jose Koilparambil in Bengaluru; Additional reporting by Maggie Fick in London; editing by Shinjini Ganguli)
